Pomerantz Law Firm Investigates Ultragenyx Pharmaceutical Investors
Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. The probe concerns potential securities fraud or other unlawful business practices.
NEW YORK – Law firm Pomerantz LLP is investigating claims on behalf of investors in Ultragenyx Pharmaceutical Inc. The investigation will determine whether the company and certain of its officers and directors engaged in securities fraud or other unlawful business practices.
The probe follows Ultragenyx Pharmaceutical's September 2, 2026, announcement of results from the Phase 3 Aspire study for its Angelman syndrome drug candidate, apazunersen (GTX-102). The company stated the study did not meet its primary endpoint nor a key secondary endpoint.
Following this news, Ultragenyx's stock price dropped $11.68, or 44.03%, to $14.85 per share on September 3, 2026. Investors holding Ultragenyx Pharmaceutical Inc. stock are advised to contact Pomerantz LLP for further information.